These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36438616)

  • 1. Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis.
    Vassilopoulos S; Vassilopoulos A; Kalligeros M; Shehadeh F; Mylonakis E
    Open Forum Infect Dis; 2022 Nov; 9(11):ofac574. PubMed ID: 36438616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
    Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis.
    Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
    Int J Clin Pharm; 2023 Dec; 45(6):1492-1495. PubMed ID: 37289318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.
    Moraes FCA; Sano VKT; Lôbo AOM; Kelly FA; Morbach V; Pasqualotto E; Burbano RMR
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials.
    Huang ZY; Jin XQ; Liang QL; Zhang DY; Han H; Wang ZW
    Medicine (Baltimore); 2023 Sep; 102(38):e35319. PubMed ID: 37747011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
    Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
    BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.
    Mian A; Naqvi SAA; Ayaz A; Husnain M; Aljama MA; Mohyuddin GR; Koehn K; Mohan M; Bin Riaz I; Chakraborty R
    Leuk Res; 2023 Aug; 131():107324. PubMed ID: 37285641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varicella zoster virus reactivation reported with isatuximab use.
    Nadeau Nguyen M; Dores GM; Nayernama A; Jones SC
    J Chemother; 2024 May; 36(3):198-201. PubMed ID: 37800850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
    Ge AY; Huang CY; Banerjee R; Knoche J; Chung A; Arora S; Martin TG; Wolf J; Wong SW; Wiita AP; Shah N
    Br J Haematol; 2023 Jun; 201(5):935-939. PubMed ID: 36846905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
    Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.
    Wang Y; Li Y; Chai Y
    J Int Med Res; 2021 Aug; 49(8):3000605211038135. PubMed ID: 34433331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis.
    Ebraheem MS; Chakraborty R; Rochwerg B; Visram A; Mohyuddin GR; Venner CP; Sandhu I; McCurdy A; Facon T; Mateos MV; Mian H
    Blood Adv; 2024 Sep; ():. PubMed ID: 39348665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.
    Paul B; Anwer F; Raza S; Mammadzadeh A; Khasawneh B; Shatnawi S; McGuirk J; Ahmed N; Mahmoudjafari Z; Mushtaq M; Abdallah AO; Atrash S
    Cancers (Basel); 2024 Aug; 16(17):. PubMed ID: 39272795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
    Balmaceda N; Aziz M; Chandrasekar VT; McClune B; Kambhampati S; Shune L; Abdallah AO; Anwer F; Majeed A; Qazilbash M; Ganguly S; McGuirk J; Mohyuddin GR
    BMC Cancer; 2021 Jun; 21(1):730. PubMed ID: 34172037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatuximab for the treatment of multiple myeloma.
    Goldsmith SR; Liu L; Covut F
    Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD38-Directed Therapies for Management of Multiple Myeloma.
    Hashmi H; Husnain M; Khan A; Usmani SZ
    Immunotargets Ther; 2021; 10():201-211. PubMed ID: 34235096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.